Fox Chase Clinical Epidemiology and Validation Center

福克斯蔡斯临床流行病学和验证中心

• 批准号: 9133740
• 负责人: PAUL Frederick ENGSTROM
• 金额: $ 24.17万
• 依托单位: RESEARCH INST OF FOX CHASE CAN CTR
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-21 至 2016-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9133740
• 关键词: Benign; Biological Assay; Biological Markers; Breast; Breast Diseases; Clinical; Collection; Community Practice; DNA; DNA Methylation; Development; Diagnostic; Early Detection Research Network; Early Diagnosis; Fox Chase Cancer Center; Foxes; Funding; Genes; Goals; Lesion; Malignant Neoplasms; Malignant neoplasm of ovary; Medical center; Methylation; Molecular; Morbidity - disease rate; Ovarian; Phase; Protein Methylation; Proteins; Proteomics; Research; Research Personnel; Research Project Grants; Risk; Serum; Specimen; Stratification; Therapeutic Human Experimentation; Tissue Sample; Tissues; Translating; U-Series Cooperative Agreements; Validation; Woman; base; cancer risk; candidate validation; clinical epidemiology; data management; data sharing; malignant breast neoplasm; meetings; mortality; multidisciplinary; outcome forecast; population based; validation studies

DESCRIPTION (provided by applicant): The overall goals of the Early Detection Research Network (EDRN) are to: a) identify biomarkers for cancer risk, early detection, molecular diagnostics, and prognosis of early cancer; and b) coordinate biomarker research and therapeutic strategies in order to reduce cancer morbidity and mortality. As a Clinical Validation Center (CVC), Fox Chase Cancer Center (FCCC) will: 1) maintain the FCCC multidisciplinary team of biomarker validation investigators; 2) comply with terms and conditions of the EDRN cooperative agreement including data sharing; 3) partner with EDRN Biomarker Development Labs (BDLs), Biomarker Reference Labs (BRLs), CVCs, and the Data Management and Coordination Center (DMCC); 4) participate in EDRN Steering Committee and Scientific meetings and activities and the EDRN Breast/Ovarian Cancer Consortium Group; 5) collect, store and distribute tissue, sera, and DNA for biomarker discovery and validation research especially from women at risk for breast and ovarian cancer; 6) partner with Geisinger Medical Center to develop population-based biomarker research validation studies. FCCC-EDRN-CVC proposes an investigator-initiated proteomic and DNA methylation phase II biomarker validation research project in women with benign breast disease (BBD) who are at risk for invasive cancer. This research utilizes biosamples collected during the past five years of EDRN funding. The aims are as follows: Study 1, Validation of candidate proteomic biomarker in BBD. Aim 1, verify that protein biomarker can distinguish preca-ncer lesions; Aim 2, validate proteomic biomarker in a set of well annotated clinical specimens. Study 2 Validations of Hypermethylated Markers. Aim 1, verify gene methylation for risk stratification in BBD; Aim 2, develop a serum-based assay in women with BBD. Numerous collaborators in and outside EDRN will utilize the FCCC-EDRN-CVC large annotated collection of breast and ovarian benign and cancer sera, DNA, and tissue samples. The proposed validation study is focused on BBD and investigates protein and DNA methylation in the same cases. The FCCC EDRN-CVC will help to translate biomarker research to community practice.

描述（由申请人提供）：早期检测研究网络（EDRN）的总体目标是：a）鉴定癌症风险、早期检测、分子诊断和早期癌症预后的生物标志物;和B）协调生物标志物研究和治疗策略，以降低癌症发病率和死亡率。作为临床验证中心（CVC），Fox Chase癌症中心（FCCC）将：1）维持由生物标志物验证研究者组成的FCCC多学科团队; 2）遵守EDRN合作协议的条款和条件，包括数据共享; 3）与EDRN生物标志物开发实验室（BDL）、生物标志物参考实验室（BRL）、CVC以及数据管理和协调中心（DMCC）合作; 4）参加EDRN指导委员会和科学会议和活动以及EDRN乳腺癌/卵巢癌联盟小组; 5）收集、储存和分发组织、血清和DNA，用于生物标志物发现和验证研究，特别是来自有乳腺癌和卵巢癌风险的女性; 6）与Geisinger医学中心合作开发基于人群的生物标志物研究验证研究。FCCC-EDRN-CVC提出了一项针对有浸润性癌症风险的良性乳腺疾病（BBD）女性的蛋白质组学和DNA甲基化II期生物标志物验证研究项目。这项研究利用了过去五年EDRN资助期间收集的生物样本。目的如下：研究1，BBD中候选蛋白质组学生物标志物的验证。目的1，验证蛋白质生物标志物对癌前病变的鉴别作用;目的2，验证蛋白质组学生物标志物在一组注释良好的临床标本中的作用。研究2高甲基化标志物的验证。目的1，验证基因甲基化对BBD风险分层的作用;目的2，开发一种基于血清的BBD女性检测方法。EDRN内外的许多合作者将利用FCCC-EDRN-CVC大量注释的乳腺和卵巢良性和癌症血清，DNA和组织样本。拟定的验证研究重点关注BBD，并研究相同情况下的蛋白质和DNA甲基化。FCCC EDRN-CVC将有助于将生物标志物研究转化为社区实践。

项目成果

Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma.

• DOI: 10.1186/bcr3111
• 发表时间: 2012-02-08
• 期刊: Breast cancer research : BCR
• 作者: Serrero G;Hawkins DM;Yue B;Ioffe O;Bejarano P;Phillips JT;Head JF;Elliott RL;Tkaczuk KR;Godwin AK;Weaver J;Kim WE
• 通讯作者: Kim WE

Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index.

• DOI: 10.1186/s13000-016-0520-4
• 发表时间: 2016-08-08
• 期刊: Diagnostic pathology
• 影响因子: 2.6
• 作者: Serrero G;Hawkins DM;Bejarano PA;Ioffe O;Tkaczuk KR;Elliott RE;Head JF;Phillips J;Godwin AK;Weaver J;Hicks D;Yue B
• 通讯作者: Yue B